Investigational New Drugs

Papers
(The H4-Index of Investigational New Drugs is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials43
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma38
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway38
A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizot34
Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells34
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors32
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study31
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma30
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA30
Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations27
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials27
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation27
A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment26
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model26
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors25
Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects24
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer23
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study23
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study21
Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer20
Challenging and new opportunities for prodrug technology20
0.064811944961548